Comparison of biparameter and multiparameter MRI in detection of clinically significant prostate cancer across PSA stratifications.
1/5 보강
[BACKGROUND] The comparative diagnostic performance of biparametric MRI (bpMRI) versus multiparametric MRI (mpMRI) for clinically significant prostate cancer (csPCa) continues to be debated.
- p-value P < 0.001
- Sensitivity 91.6%
- Specificity 91.0%
APA
Jin P, Ding Z, et al. (2025). Comparison of biparameter and multiparameter MRI in detection of clinically significant prostate cancer across PSA stratifications.. BMC medical imaging, 25(1), 346. https://doi.org/10.1186/s12880-025-01884-x
MLA
Jin P, et al.. "Comparison of biparameter and multiparameter MRI in detection of clinically significant prostate cancer across PSA stratifications.." BMC medical imaging, vol. 25, no. 1, 2025, pp. 346.
PMID
40855538 ↗
Abstract 한글 요약
[BACKGROUND] The comparative diagnostic performance of biparametric MRI (bpMRI) versus multiparametric MRI (mpMRI) for clinically significant prostate cancer (csPCa) continues to be debated. This study aimed to compare mpMRI and bpMRI in detecting csPCa across prostate-specific antigen (PSA) strata and identify supplementary tools comparable to dynamic contrast-enhanced (DCE) imaging.
[METHODS] Images were evaluated using mpMRI-based mp-PI-RADS and bpMRI-based bp-PI-RADS and simplified PI-RADS (S-PI-RADS) schemes. The lesion volume (LV) was manually segmented by a radiologist using ITK-SNAP software on high b-value DWI images. The diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis. The differences of T2WI-score, DCE assessment and LV between csPCa and non-csPCa in peripheral zone (PZ) with DWI category 3 were compared.
[RESULTS] For overall PSA, mp-PI-RADS and bp-PI-RADS showed comparable AUCs (0.889 vs. 0.882; P > 0.05). When PSA ≤ 10 ng/ml, mp-PI-RADS exhibited the highest specificity (91.0% vs. bp-PI-RADS: 64.4%, S-PI-RADS: 75.0%) and PPV (73.0% vs. bp-PI-RADS: 47.7%, S-PI-RADS: 52.5%). When PSA > 10 ng/ml, S-PI-RADS demonstrated higher sensitivity (91.6% vs. mp-PI-RADS: 83.2%, bp-PI-RADS: 81.2%) and F1-score (0.873 [0.822-0.924] vs. mp-PI-RADS: 0.832 [0.778-0.886], bp-PI-RADS: 0.831 [0.777-0.885]). Among DWI category 3 PZ lesions, neither DCE nor T2WI significantly stratified csPCa risk (P = 0.657 and P = 0.424), whereas LV ≥ 0.5 cm³ showed markedly higher csPCa risk (83.8% vs. 45.8%; P < 0.001).
[CONCLUSIONS] While mpMRI and bpMRI exhibit comparable overall diagnostic performance but context-dependent strengths: mpMRI demonstrates higher specificity for avoiding unnecessary biopsies when PSA ≤ 10 ng/ml, whereas bpMRI (particularly S-PI-RADS) maximizes sensitivity for csPCa detection when PSA > 10 ng/ml. LV is anticipated to serve as a complementary radiological biomarker at the absence of DCE.
[METHODS] Images were evaluated using mpMRI-based mp-PI-RADS and bpMRI-based bp-PI-RADS and simplified PI-RADS (S-PI-RADS) schemes. The lesion volume (LV) was manually segmented by a radiologist using ITK-SNAP software on high b-value DWI images. The diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis. The differences of T2WI-score, DCE assessment and LV between csPCa and non-csPCa in peripheral zone (PZ) with DWI category 3 were compared.
[RESULTS] For overall PSA, mp-PI-RADS and bp-PI-RADS showed comparable AUCs (0.889 vs. 0.882; P > 0.05). When PSA ≤ 10 ng/ml, mp-PI-RADS exhibited the highest specificity (91.0% vs. bp-PI-RADS: 64.4%, S-PI-RADS: 75.0%) and PPV (73.0% vs. bp-PI-RADS: 47.7%, S-PI-RADS: 52.5%). When PSA > 10 ng/ml, S-PI-RADS demonstrated higher sensitivity (91.6% vs. mp-PI-RADS: 83.2%, bp-PI-RADS: 81.2%) and F1-score (0.873 [0.822-0.924] vs. mp-PI-RADS: 0.832 [0.778-0.886], bp-PI-RADS: 0.831 [0.777-0.885]). Among DWI category 3 PZ lesions, neither DCE nor T2WI significantly stratified csPCa risk (P = 0.657 and P = 0.424), whereas LV ≥ 0.5 cm³ showed markedly higher csPCa risk (83.8% vs. 45.8%; P < 0.001).
[CONCLUSIONS] While mpMRI and bpMRI exhibit comparable overall diagnostic performance but context-dependent strengths: mpMRI demonstrates higher specificity for avoiding unnecessary biopsies when PSA ≤ 10 ng/ml, whereas bpMRI (particularly S-PI-RADS) maximizes sensitivity for csPCa detection when PSA > 10 ng/ml. LV is anticipated to serve as a complementary radiological biomarker at the absence of DCE.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Multiparametric Magnetic Resonance Imaging
- Aged
- Middle Aged
- Contrast Media
- Magnetic Resonance Imaging
- Sensitivity and Specificity
- Diffusion Magnetic Resonance Imaging
- Retrospective Studies
- ROC Curve
- Biparametric MRI
- Clinically significant prostate cancer
- Comparison
- Multiparametric MRI
- Simplified prostate imaging report and data system
같은 제1저자의 인용 많은 논문 (5)
- Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.
- Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.
- Correction: Identification of prognosis and therapy related intratumoral microbiome and immune signatures in gastric cancer.
- Identification of prognosis and therapy related intratumoral microbiome and immune signatures in gastric cancer.
- Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.